Types of Paraneoplastic Syndromes
Paraneoplastic syndromes are broadly categorized into neurologic, endocrine, dermatologic, rheumatologic, hematologic, and ophthalmologic types, with neurologic and endocrine syndromes being the most clinically significant and commonly encountered in lung cancers. 1
Major Categories of Paraneoplastic Syndromes
Neurologic Paraneoplastic Syndromes
The neurologic syndromes represent some of the most debilitating paraneoplastic manifestations and include:
Lambert-Eaton Myasthenic Syndrome (LEMS): Presents with proximal leg weakness caused by antibodies against voltage-gated calcium channels. This is particularly associated with small cell lung cancer (SCLC) 1
Paraneoplastic Encephalomyelitis: Caused by anti-Hu antibodies that cross-react with both tumor antigens and human neuronal RNA-binding proteins, resulting in multiple neurologic deficits. Notably, this syndrome may precede the actual tumor diagnosis 1
Sensory Neuropathy: Also mediated by anti-Hu antibodies, causing peripheral nerve dysfunction 1
Other neurologic syndromes: Include subacute cerebellar degeneration, myasthenia gravis, opsoclonus-myoclonus, and limbic encephalitis 2, 3, 4
Critical clinical pearl: When neurologic paraneoplastic syndrome is suspected, obtaining a comprehensive paraneoplastic antibody panel should be considered 1. The 2021 diagnostic criteria emphasize testing should be restricted to high-risk or intermediate-risk syndromes to maintain diagnostic value 5.
Endocrine Paraneoplastic Syndromes
Endocrine manifestations result from aberrant hormone production by tumor cells:
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): The most common endocrine paraneoplastic syndrome in SCLC, caused by ectopic vasopressin (ADH) production leading to hyponatremia 1. Primary treatment includes fluid restriction and demeclocycline, with vasopressin receptor inhibitors (conivaptan, tolvaptan) reserved for refractory cases 1
Cushing Syndrome: Results from ectopic ACTH production, though occurs less frequently than SIADH in SCLC patients 1, 4
Humoral Hypercalcemia of Malignancy: Most commonly associated with squamous cell carcinoma rather than SCLC 2, 6
Carcinoid Syndrome: Uncommon in lung neuroendocrine tumors (LNETs), with only 13% of carcinoid syndrome cases having lung as the primary site 7
Other endocrine syndromes: Include paraneoplastic acromegaly, hypoglycemia, and osteomalacia/rickets 3, 6
Dermatologic and Rheumatologic Syndromes
Hypertrophic Osteoarthropathy: Characterized by digital clubbing and periosteal new bone formation 2, 3
Paraneoplastic Pemphigus: An autoimmune blistering disorder 3
Hematologic Syndromes
Trousseau's Syndrome: Paraneoplastic coagulopathy leading to venous thromboembolism 2
Various cytopenias and thrombocytosis 2
Other Syndromes
Important Clinical Considerations
The histological type of lung cancer strongly predicts the associated syndrome: SIADH is most common with SCLC, while hypercalcemia typically occurs with squamous cell carcinoma 2.
Timing matters: Symptoms often precede the cancer diagnosis, particularly neurologic and dermatologic manifestations 2. This makes recognition of these syndromes crucial for early cancer detection.
Treatment approach: Treating the underlying malignancy is generally the most effective therapy for paraneoplastic syndromes, with early treatment after symptom onset offering the best potential for improvement 2. However, complete resolution of neurologic syndromes is rare even with successful cancer treatment 4.
Diagnostic pitfall: The 2015 terminology was updated from "paraneoplastic syndromes" to "functional syndromes" for LNETs, and biochemical testing should be limited to patients with appropriate clinical symptoms and signs rather than routine screening 7. Indiscriminate antibody testing decreases diagnostic value 5.
Hyponatremia in SCLC requires careful evaluation: Cancer treatment itself (cisplatin, opiates) can also cause hyponatremia, not just SIADH 1. Hyponatremia typically improves after successful SCLC treatment 1.